STUB1 and type 2 diabetes mellitus: The subgroup analysis showed that CHIP carriers in the hyperLDLC group had an ~2-fold higher risk of developing new-onset type 2 diabetes than non-CHIP carriers in the non-hyperLDLC group (HR 2.05, 95% CI 1.40–3.00, p < 0.001).